Search Clinical Trials
598,002 trials
ID
Status
Phase
Title
Sponsor
NCT07761923
Preserving Muscle Mass During Incretin-Induced Weight LossKarolinska InstitutetNot Yet RecruitingNot Applicable
NCT07761923Not Yet Recruiting
Not Applicable
Preserving Muscle Mass During Incretin-Induced Weight LossKarolinska Institutet
NCT07760545
Reliability In Neurocognitive Telemedicine Screening (RING)University of British ColumbiaRecruiting
NCT07760545Recruiting
—
Reliability In Neurocognitive Telemedicine Screening (RING)University of British Col...
NCT07760948
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting SemaglutideAmerican Diabetes AssociationNot Yet RecruitingPhase 2
NCT07760948Not Yet Recruiting
Phase 2
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting SemaglutideAmerican Diabetes Associa...
NCT07761598
The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) STUDY.Jacobs instituteNot Yet RecruitingNot Applicable
NCT07761598Not Yet Recruiting
Not Applicable
The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) STUDY.Jacobs institute
NCT07759193
Energy Expenditure Assessment in Head and Neck Cancer Patients Treated With Free Flap SurgeryTel-Aviv Sourasky Medical CenterRecruitingNot Applicable
NCT07759193Recruiting
Not Applicable
Energy Expenditure Assessment in Head and Neck Cancer Patients Treated With Free...Tel-Aviv Sourasky Medical...
NCT07759323
Polygonatum Sibiricum Reduces Visceral Fat in Obese AdultsZhejiang Provincial Tongde HospitalNot Yet RecruitingNot Applicable
NCT07759323Not Yet Recruiting
Not Applicable
Polygonatum Sibiricum Reduces Visceral Fat in Obese AdultsZhejiang Provincial Tongd...
NCT07760155
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus ErythematosusShanghai Escugen Biotechnology Co., LtdNot Yet RecruitingPhase 2
NCT07760155Not Yet Recruiting
Phase 2
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibod...Shanghai Escugen Biotechn...
NCT07761455
Prophylactic IABP in Delayed-Presentation Anterior STEMIQilu Hospital of Shandong UniversityNot Yet RecruitingNot Applicable
NCT07761455Not Yet Recruiting
Not Applicable
Prophylactic IABP in Delayed-Presentation Anterior STEMIQilu Hospital of Shandong...
NCT07760051
Effect of Agent-assisted, LLM-assisted and Traditional Workflows on Physician Admission DiagnosisSecond Affiliated Hospital, Zhejiang University, School of MedicineNot Yet RecruitingNot Applicable
NCT07760051Not Yet Recruiting
Not Applicable
Effect of Agent-assisted, LLM-assisted and Traditional Workflows on Physician Ad...Second Affiliated Hospita...
NCT07761169
Randomized Controlled Trial of the SurgDiff Model for Predicting Surgical Difficulty to Help Choose Approach in Mid-Low Rectal CancerPeking Union Medical College HospitalNot Yet RecruitingNot Applicable
NCT07761169Not Yet Recruiting
Not Applicable
Randomized Controlled Trial of the SurgDiff Model for Predicting Surgical Diffic...Peking Union Medical Coll...
NCT07759661
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination TherapiesIRCCS San RaffaeleNot Yet Recruiting
NCT07759661Not Yet Recruiting
—
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Perso...IRCCS San Raffaele
NCT07761013
Yanlishuang Buccal Dropping Pills for Acute PharyngitisBeijing University of Chinese MedicineNot Yet RecruitingNot Applicable
NCT07761013Not Yet Recruiting
Not Applicable
Yanlishuang Buccal Dropping Pills for Acute PharyngitisBeijing University of Chi...
NCT07760766
Auricular Acupressure for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic ChemotherapyChina Medical University, ChinaNot Yet RecruitingNot Applicable
NCT07760766Not Yet Recruiting
Not Applicable
Auricular Acupressure for Prevention of Chemotherapy-Induced Nausea and Vomiting...China Medical University,...
NCT07760454
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple MyelomaUCARsgen Biotech LimitedNot Yet RecruitingPhase 1
NCT07760454Not Yet Recruiting
Phase 1
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple MyelomaUCARsgen Biotech Limited
NCT07760350
Assessing the Feasibility of the "Heart Care Pairs" InterventionNational Institute on Minority Health and Health Disparities (NIMHD)Not Yet RecruitingNot Applicable
NCT07760350Not Yet Recruiting
Not Applicable
Assessing the Feasibility of the "Heart Care Pairs" InterventionNational Institute on Min...
NCT07760519
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLCAstraZenecaNot Yet Recruiting
NCT07760519Not Yet Recruiting
—
A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adul...AstraZeneca
NCT07759115
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility StudyNational Institute of Nursing Research (NINR)Not Yet RecruitingNot Applicable
NCT07759115Not Yet Recruiting
Not Applicable
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feas...National Institute of Nur...
NCT07760779
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief MindfulnessNational Institute on Aging (NIA)Not Yet RecruitingNot Applicable
NCT07760779Not Yet Recruiting
Not Applicable
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and B...National Institute on Agi...
NCT07761793
Diaphragmatic Myofascial Release Added to Neck Exercises for Chronic Neck PainAbdelrahman AlghoulNot Yet RecruitingNot Applicable
NCT07761793Not Yet Recruiting
Not Applicable
Diaphragmatic Myofascial Release Added to Neck Exercises for Chronic Neck PainAbdelrahman Alghoul
NCT07759466
Hippo Signaling Pathway Proteins in Gingival Crevicular Fluid of Individuals With Periodontal DiseaseHarvard UniversityCompleted
NCT07759466Completed
—
Hippo Signaling Pathway Proteins in Gingival Crevicular Fluid of Individuals Wit...Harvard University
Result Breakdown
Not yet recruiting17 (85%)
Recruiting2 (10%)
Completed1 (5%)
not_applicable13 (65%)
Not Specified4 (20%)
Phase 22 (10%)
Phase 11 (5%)